UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Treatment of patients with stage I focal anaplastic and diffuse anaplastic Wilms tumour: A report from the SIOP-WT-2001 GPOH and UK-CCLG studies

Mifsud, W; Furtwängler, R; Vokuhl, C; D'Hooghe, E; Pritchard-Jones, K; Graf, N; Vujanić, GM; (2022) Treatment of patients with stage I focal anaplastic and diffuse anaplastic Wilms tumour: A report from the SIOP-WT-2001 GPOH and UK-CCLG studies. European Journal of Cancer , 166 pp. 1-7. 10.1016/j.ejca.2022.01.036. Green open access

[thumbnail of Article]
Preview
Text (Article)
Main manuscript final.pdf - Accepted Version

Download (576kB) | Preview
[thumbnail of Tables]
Preview
Text (Tables)
Tables 1-3.pdf - Accepted Version

Download (567kB) | Preview
[thumbnail of Figure]
Preview
Text (Figure)
Figure 1A. Event-free survival.pdf - Accepted Version

Download (8kB) | Preview
[thumbnail of Figure]
Preview
Text (Figure)
Figure 1B. Overall survival.pdf - Accepted Version

Download (8kB) | Preview

Abstract

Background: Anaplasia is an unfavourable prognostic histological feature in Wilms tumour (WT). Patients with stage I anaplastic WT (AWT) typically achieve good outcomes, albeit with more treatment than for stage I non-AWT. Since the SIOP-WT-2001 study, patients with focal AWT (FAWT) have been classified as intermediate risk and received less intense treatment than patients with diffuse AWT (DAWT). The aim of the study was to analyse outcomes in these patients. Patients and methods: This was a retrospective analysis of clinicopathological features and outcomes of 59 patients with stage I AWT (19 FAWT, 40 DAWT) from the SIOP-WT-2001 GPOH and UK-CCLG groups. The patients with FAWT were treated as intermediate-risk WT, with 8 weeks of vincristine and actinomycin D (4 weeks pre-operatively, and 4 weeks post-operatively). For comparison, we also assessed outcomes in 818 patients with stage I intermediate-risk non-AWT (IR-non-AWT). The patients with DAWT were treated with vincristine, actinomycin D and doxorubicin for 31 weeks. No group received radiotherapy. Results: Median follow-up was 67.6 months; 4-year event-free survival and overall survival were 87% (95% confidence interval [CI] = 72–100) and 100%, respectively, in the FAWT group, 85% (95% CI = 74–98) and 93% (95% CI 85–100), respectively, in the DAWT group and 91% (95% CI = 89–93) and 98% (95% CI = 97–99), respectively, in the IR-non-AWT group. Conclusions: Outcomes for patients with stage I FAWT were comparable with those of other, identically treated, patients with stage I IR-non-AWT. Patients with stage I DAWT also showed good outcomes, albeit with more intensive chemotherapy than IR-non-AWT, but without radiotherapy.

Type: Article
Title: Treatment of patients with stage I focal anaplastic and diffuse anaplastic Wilms tumour: A report from the SIOP-WT-2001 GPOH and UK-CCLG studies
Location: England
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.ejca.2022.01.036
Publisher version: https://doi.org/10.1016/j.ejca.2022.01.036
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Anaplasia, Focal and diffuse, Outcomes, Stage I, Wilms tumour
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Developmental Biology and Cancer Dept
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
URI: https://discovery.ucl.ac.uk/id/eprint/10147187
Downloads since deposit
71Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item